The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Astria Therapeutics To Present New STAR-0215 Preclinical Results At The 2021 American College of Allergy, Asthma And Immunology Annual Scientific Meeting
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share new preclinical results for STAR-0215 in a
Jefferies Initiates Coverage On Astria Therapeutics with Buy Rating, Announces Price Target of $20
Jefferies analyst Eun Yang initiates coverage on Astria Therapeutics (NASDAQ:ATXS) with a Buy rating and announces Price Target of $20.